首页 | 本学科首页   官方微博 | 高级检索  
相似文献
 共查询到20条相似文献,搜索用时 159 毫秒
1.
尼麦角林治疗轻度认知功能障碍的疗效观察   总被引:1,自引:0,他引:1  
本研究应用尼麦角林治疗36例轻度认知功能障碍(MCI)患者,并与服用吡拉西坦治疗的患者比较,以观察尼麦角林治疗MCI的疗效.  相似文献   

2.
尼麦角林联合奥拉西坦治疗脑卒中后血管性认知功能障碍   总被引:1,自引:0,他引:1  
目的观察尼麦角林联合奥拉西坦治疗脑卒中后血管性认知功能障碍的临床疗效。方法将120例脑卒中后认知功能障碍患者随机分为尼麦角林组和联合组,分别给予尼麦角林、尼麦角林联合奥拉西坦治疗,2组均治疗1个月。2组治疗前后采用蒙特利尔认知评估量表(MoCA)进行认知功能评分,比较临床疗效。结果联合组MoCA评分提高的均数为(5.97±2.06)分,高于尼麦角林组的(3.53±1.44)分,MoCA评分的变化最显著,尼麦角林组和联合组差异有统计学意义(t=4.21,P0.01),联合组有效率最高,总有效率为93.3%。结论尼麦角林和奥拉西坦是治疗血管性认知功能障碍(VCI)的有效药物,两者联合用药较单一应用尼麦角林效果好,两者联合使用能显著改善脑卒中后血管性认知功能障碍患者的症状严重程度和生活质量,临床疗效确切。  相似文献   

3.
目的 观察尼麦角林治疗脑梗死伴认知功能障碍的疗效.方法 对60例伴有认知功能障碍的脑梗死患者随机分为治疗组和对照组,在常规药物治疗的基础上,治疗组加用尼麦角林片,3次/d,每次口服10mg,连用3个月.在治疗前和治疗后3个月,采用简易智力状态检查量表(MMSE)、中国脑卒中临床神经功能缺损程度评分量表(CSS)、巴氏指数(BI)评定患者的功能.结果 治疗组患者的认知功能改善明显优于对照组(P<0.01).结论 尼麦角林能改善脑梗死患者的认知功能.  相似文献   

4.
目的研究天智颗粒联合尼麦角林治疗血管性痴呆的有效性和安全性。方法将血管性痴呆病人60例按随机单盲法分为2组,每组30例,对照组给予尼麦角林口服,治疗组在尼麦角林治疗基础上加服天智颗粒,共12周。2组用药前后均进行认知障碍程度检查和痴呆度评分,以日常生活能力量表(ADL)和简易精神状态检查(MMSE)为症状改善的评估指标。结果治疗前2组MMSE评分、ADL评分无显著性差异(P>0.05),对照组用药后MMSE评分明显改善(P<0.05),治疗组MMSE评分显著改善(P<0.01);组间比较治疗组的改善效果明显优于对照组(P<0.01)。对照组ADL用药后评分明显改善(P<0.05),治疗组用药后ADL评分显著改善(P<0.01);治疗组的改善效果亦明显优于对照组(P<0.01)。结论天智颗粒联合尼麦角林能显著改善血管性痴呆患者的认知功能和日常生活能力。  相似文献   

5.
尼麦角林治疗血管性痴呆的前瞻性、双盲、多中心研究   总被引:8,自引:0,他引:8  
目的验证尼麦角林治疗轻至中度认知功能障碍的血管性痴呆的有效性和安全性.方法前瞻性、随机双盲、阳性药对照的多中心临床试验.入组的110例病人均符合美国精神障碍诊断与统计手册DSM-Ⅲ血管性痴呆的诊断标准.以简易精神状态检查(MMSE)和韦克斯勒记忆量表(WMS)为主要评价指标,日常生活能力量表(ADL)和临床综合调查表(CGI)为次要评价指标.结果实际可评估病例103例,两组MMSE评分在治疗后均有提高,尼麦角林组提高更明显(分别为1.62±2.33、2.88±2.85);尼麦角林组WMS评分在治疗后有明显提高(5.04±10.61),阿尼西坦组治疗前后WMS评分无明显差异(1.98±9.49);两组治疗后ADL和CGI的SI均降低;尼麦角林组总有效率为80.0%,阿尼西坦组为56.6%.两组均无明显药物相关的不良反应.结论尼麦角林能改善血管性痴呆病人的认知功能,且其疗效优于阿尼西坦,应用尼麦角林每天60mg时具有相当的安全性.  相似文献   

6.
目的研究血管性痴呆患者采用尼麦角林联合盐酸多奈哌齐的治疗效果。方法抽取2014-03—2015-06在我院治疗的60例血管性痴呆进行分组研究,随机分为观察组与对照组各30例,对照组服用尼麦角林,观察组联合服用尼麦角林及盐酸多奈哌齐,对比观察2组患者治疗效果及日常生活能力量表评分(ADL)、简易智能状态检查量表评分(MMSE)和不良反应。结果观察组治疗总有效率80.00%,对照组56.67%,差异有统计学意义(P0.05);治疗前观察组与对照组ADL及MMSE评分对比,差异无统计学意义(P0.05);经治疗后,观察组ADL评分明显低于对照组,MMSE评分均明显高于对照组,差异有统计学意义(P0.05);2组患者均未出现不良反应。结论采用尼麦角林联合盐酸多奈哌齐治疗血管性痴呆患者疗效确切,治疗有效率较高,安全性较高,能够显著改善患者认知功能和日常生活能力,对提高患者生活质量具有重要意义,值得推广运用。  相似文献   

7.
目的 探讨尼麦角林对因头颈部肿瘤采取放疗治疗致放射性脑损伤患者脑功能重塑的影响.方法 回顾性分析我院与三九脑科医院2010-01-2014-01收治的84例放射治疗致脑损伤的患者的临床资料,随机分为观察组和对照组各42例,对照组行常规康复治疗,观察组在对照组基础上加用尼麦角林.比较2组康复治疗前及康复治疗后第2周、4周相关神经功评分及治疗4周后头痛症状、MRI病灶变化分级等指标差异.结果 观察组神经功能缺损程度评分、ADL、MESSS评分改善均显著优于对照组,差异均有统计学意义(P<0.05).观察组头痛症状分布和总有效率显著优于对照组,差异均具有统计学意义(P<0.05),头颅MRI病灶变化显效率及总有效率均显著高于对照组,差异均有统计学意义(P<0.05).结论 尼麦角林对于放射性脑损伤脑功能重建有积极作用,值得临床应用推广.  相似文献   

8.
目的观察盐酸多奈哌齐联合尼麦角林治疗老年性痴呆的临床疗效。方法治疗组应用盐酸多奈哌齐片,尼麦角林胶囊;对照组应用吡拉西坦片,2组均在治疗3、6个月后统计疗效。结果治疗组治疗后与治疗前疗效、MMSE、ADL评分,均好于对照组(P<0.05,P<0.01),未见明显的不良反应。结论盐酸多奈哌齐与尼麦角林联合应用能明显改善老年痴呆患者的记忆力、定向力、认知能力和生活自理能力,是一种有效治疗老年痴呆的手段。  相似文献   

9.
目的探讨尼麦角林对偏头痛患者脑血流动力学与血浆5-羟色胺(5-HT)水平的影响。方法选择67例偏头痛患者随机分为尼麦角林治疗组(35例)和对照组(32例),同时选择30例健康体检者为健康对照组,治疗组应用尼麦角林治疗,对照组应用双氯芬酸钠治疗,应用经颅多普勒超声(TCD)技术检测治疗组和对照组治疗前后及健康对照组双侧大脑中动脉、大脑前动脉、椎动脉和基底动脉的(mean velocity,Vm)变化。采用高效液相色谱紫外光法测定3组血浆5-HT浓度,比较3组颅内动脉血流动力学的改变与血浆5-HT水平。结果 67例服药前大脑前动脉、大脑中动脉、椎动脉和基底动脉的平均血流速度与健康对照组比较增快。治疗后对照组变化不明显,治疗组大脑前动脉、大脑中动脉、椎动脉和基底动脉的平均血流速度降低,且与健康对照组比较差异无统计学意义(P0.05)。与健康对照组比较,偏头痛患者(治疗组和对照组)发作期血浆5-HT水平降低,发作间期血浆5-HT水平升高,差异有统计学意义(P0.05)。治疗后治疗组血浆5-HT水平发作期较治疗前和对照组显著升高,发作间期较治疗前和对照组明显下降(P0.05)。结论尼麦角林可明显预防和减轻偏头痛患者的发作,改善偏头痛患者的脑血流,调节偏头痛患者发作期和发作间期的血浆5-HT水平可能是其作用机制之一。  相似文献   

10.
目的:探讨尼麦角林治疗偏头痛的疗效及对神经心理因素的影响。方法138例偏头痛患者随机分为2组,治疗组口服尼麦角林片10 mg ,3次/d ,同时在疼痛发作时口服双氯芬酸钠片50 mg ,q12h;对照组仅在发作时口服双氯芬酸钠。所有患者入组时进行16PF测定;治疗前及治疗后2周及8周进行HAMA、HAMD评定及疼痛指数测定。结果16PF评定显示偏头痛患者恃强性、敏感性、怀疑性、幻想性、忧虑性、自律性、紧张性因子分高于正常人常模,差异有统计学意义(P<0.05)。治疗组疗效优于对照组,差异有统计学意义(P<0.05)。第8周末治疗组AMD、HAMA评分及减分率较对照组差异有统计学意义( P<0.05)。结论联合应用尼麦角林及发作期使用双氯芬酸钠对症治疗偏头痛可提高疗效,同时改善焦虑及抑郁情绪。  相似文献   

11.
There is growing interest in identifying Parkinson's disease (PD) patients with mild cognitive impairment (PD‐MCI), but widely disparate criteria have been used. We assessed 143 PD patients and 50 matched controls on 20 measures across 4 cognitive domains (executive function, attention and working memory, learning and memory, visuoperception). Twenty‐four patients met criteria for dementia (PD‐D); nondementia patients were classified as either with normal cognition or MCI for 12 neuropsychological criteria. We compared the influence of these criteria on the distribution of global cognitive performance in the resulting PD‐MCI groups relative to the control and PD‐D groups. Different criteria produced substantial variation in the proportion of PD‐MCI cases identified. Fourteen percent PD‐MCI was found when using 2 scores in 1 domain at 2 standard deviations (SD) below normative scores, with no controls identified as MCI, through to 89% PD‐MCI with 1 score in 1 domain at 1 SD below normative scores, when 70% of controls were identified as MCI. The balance of cases with impaired cognition but not those with generally intact cognition was better served by using criteria that required 2 specific deficit scores or deficits across 2 domains. As comparisons with external normative data may have greater applicability across centers, we suggest that 2 scores at ?1.5 SD within any single domain (30% PD‐MCI) or 1 score at ?1.5 SD in each of 2 domains (37% PD‐MCI) provide suitable criteria to minimize the inclusion of cognitively well patients. Clinical dementia rating did not improve the relative identification of cognitively impaired and unimpaired nondementia PD patients. © 2011 Movement Disorder Society  相似文献   

12.
This study examined the use of the Hong Kong version of the Rivermead Behavioral Memory Test—Third Edition (RBMT-3) for older adults, and by presenting the optimal cut-off scores for patients with cognitive impairments, and for a group of peers who have functional everyday cognition. Hundred older adults residing in community dwellings were recruited from three non-government organisations and completed the RBMT-3: 29 patients with mild to moderate dementia, 34 persons at risk for MCI, and 37 matched older adults with everyday functional cognition for a healthy control group (NC). The test has excellent inter-rater (ICC [2, 1]?=?0.997), intra-rater (ICC [3, 1]?=?0), and parallel version (ICC [3, 1]?=?0.990) reliabilities, as well as satisfactory internal consistency (Cronbach’s alpha: 0.643–0.832). The scores of the MCI group were significantly lower than those of NC group in four subtests. The optimal cut-off scaled scores of?≤?41.5,?≤?102.5, and?≤?131.5 are suggested for the RBMT-3 to discriminate between patients with mild and moderate dementia, mild dementia and MCI, and MCI and NC, with sensitivities 73%, 100% and 94.1%, respectively. This version is useful to differentiate those with or without risk of cognitive impairments.  相似文献   

13.
目的 探究团体认知行为治疗对双相障碍患者病耻感和服药依从性的影响.方法25例患者根据配对设计分为研究组16例和对照组9例,研究组在常规治疗基础上接受团体认知行为治疗,对照组接受常规治疗,采用精神疾病病耻感量表(ISMI)和药物依从性评价量表(MARS)测评病耻感和服药依从性.结果10次治疗后,两组患者病耻感组间比较,研究组较对照组刻板印象的认可因子改善明显,差异有统计学意义(P<0.05);组内比较,研究组疏远因子、刻板印象的认可因子、歧视经历因子和病耻感总分优于治疗前,差异有统计学意义(P<0.05),而对照组总分及各因子分治疗前后比较差异均无统计学意义(P>0.05).两组患者服药依从性组间比较,两组治疗前后差异均无统计学意义(P>0.05);组内比较,研究组服药依从性优于治疗前,差异有统计学意义(P<0.05),而对照组差异无统计学意义(P>0.05).结论团体认知行为治疗可降低双相障碍患者的病耻感,提高服药依从性,对促进疾病的康复具有重要意义.  相似文献   

14.
Screening for mild cognitive impairment: comparing the SMMSE and the ABCS.   总被引:1,自引:0,他引:1  
OBJECTIVE: To compare the sensitivity and specificity of the AB Cognitive Screen (ABCS) with the Standardized Mini-Mental State Examination (SMMSE) to differentiate normal cognition from mild cognitive impairment (MCI), especially when educational level and age are taken into account. METHOD: This cross-sectional study took place at geriatric outpatient memory clinics. Participants were community-dwelling adults, aged 55 years or over, referred from primary care settings (a minority of participants were referred from specialists) for assessment of memory loss and age-matched control subjects with no complaint of memory loss. Each participant had the ABCS and the SMMSE administered in random order on the same day. RESULTS: Participants included 124 patients diagnosed with MCI and 111 with normal cognitive function. The ABCS showed a statistically significant difference between normal cognition and MCI (ABCS score 111.7 and 104.6 points, respectively, P < 0.001) for the whole group. This difference was significant with the ABCS, regardless of participants' age or education. There was a significant difference between normal cognition and MCI for SMMSE scores (SMMSE score 27.8 and 27.2 points, respectively, P = 0.040), but the differences were not significant when age and education were taken into account. Age and education were shown to affect the scores of both instruments except for the ABCS scores of MCI subjects, which were not significantly affected by education (P = 0.059). CONCLUSIONS: The ABCS is more sensitive than the SMMSE in differentiating normal cognition from MCI. The ABCS appears to be less influenced by education. It has improved clinical utility with a wider range of scoring gradations, reduced ceiling effects, and shorter scoring and administration times.  相似文献   

15.
目的联合磁共振波谱(Magnetic Resonance Spectrum,MRS)分析及CT灌注成像(CT perfusion imaging,CTP)观察尤瑞克林对大面积脑梗死患者的临床疗效。方法将62例大面积脑梗死患者,随机分为尤瑞克林治疗组(试验组)和常规治疗组(对照组)各31例;两组患者均给予常规内科处理(包括合并高血压、糖尿病、心脏病等的一般药物治疗),试验组在常规治疗的基础上加用尤瑞克林治疗。采用NIHSS评分评价治疗前及治疗后14 d患者神经功能缺损变化。采用Barthel指数记分法评定日常生活活动能力(ADL)记录患者治疗前及治疗后14 d、30 d、90 d的评分。用MRS分析患者治疗前及治疗后14 d脑梗死组织代谢物N-乙酰天门冬氨酸(NAcetylpartate,NAA)、胆碱(Choline,Cho)、肌酸(Creatine,Cr)及乳酸(Lactate,Lac)的含量。用CTP分析治疗前及治疗后14 d梗死区rCBF、rCBV、rTTP和rMTT指标。结果治疗前两组患者NIHSS评分、Barthel指数、hs-CRP水平、MRS及CTR的各检测指标的差异无显著性意义(P>0.05);治疗后,发现各组患者上述指标均较治疗前明显改善(P<0.05);但尤瑞克林组的改善幅度尤为显著,两组间差异均具有显著性意义(P<0.05)。结论尤瑞克林可明显改善大面积脑梗死患者的神经功能缺损和日常生活能力,作用机制可能是通过改善梗死区的微循环和神经细胞的代谢。  相似文献   

16.

Objective

The aim of this systematic review and meta-analysis was to evaluate the efficacy of noninvasive brain stimulation (NIBS) on cognition using functional magnetic resonance imaging (fMRI) in patients with mild cognitive impairment (MCI) and Alzheimer's disease (AD), thus providing the neuroimaging mechanism of cognitive intervention.

Methods

English articles published up to April 30, 2023 were searched in the PubMed, Web of Science, Embase, and Cochrane Library databases. We included randomized controlled trials where resting-state fMRI was used to observe the effect of NIBS in patients with MCI or AD. RevMan software was used to analyze the continuous variables, and SDM-PSI software was used to perform an fMRI data analysis.

Results

A total of 17 studies comprising 258 patients in the treatment group and 256 in the control group were included. After NIBS, MCI patients in the treatment group showed hyperactivation in the right precuneus and decreased activity in the left cuneus and right supplementary motor area. In contrast, patients in the control group showed decreased activity in the right middle frontal gyrus and no hyperactivation. The clinical cognitive scores in MCI patients were significantly improved by NIBS, while not in AD. Some evidence regarding the modulation of NIBS in resting-state brain activity and functional brain networks in patients with AD was found.

Conclusions

NIBS could improve cognitive function in patients with MCI and AD. fMRI evaluations could be added to evaluate the contribution of specific NIBS treatment therapeutic effectiveness.  相似文献   

17.
OBJECTIVE: This study examined the short-term effects of first- and second-generation antipsychotic medications on social cognition and basic cognition. METHOD: One hundred patients with schizophrenia or schizoaffective disorder participated in an 8 week, double-blind study of risperidone, olanzapine, and haloperidol. Participants were administered multiple measures of social cognition, basic cognition, and clinical symptoms at baseline, the end of week 4, and the end of week 8. Seventy-three patients completed the baseline assessment and at least one other assessment. Data were analyzed with mixed-effects analyses of covariance. For data reduction, the social cognitive measures were clustered into a summary score, and the cognitive measures were clustered into two summary scores: general cognitive ability and processing speed. RESULTS: There were no treatment-related differences on any of the three summary scores. Social cognition did not show within-group changes over time either by itself or after control for the cognitive clusters. One cognitive score (general cognitive ability) increased during the study period for all three medication groups. CONCLUSIONS: The present study included a rather thorough assessment of social cognition and did not find any evidence of between-group or within-group effects of antipsychotic medication on social cognition.  相似文献   

18.
目的:探讨statins(阿托伐他汀)对不同载脂蛋白E(ApoE)基因型的轻度认知障碍(MCl)患者认知功能的影响。方法:76例MCI患者按是否携带ApoEε4基因以及是否给予statins分为四组,比较1年前后的血脂水平及MMSE评分。结果:Statins可降低总胆固醇(TC)和低密度脂蛋白(LDL)水平。与不携带ApoEε4等位基因(ε4-)者比较,携带者(ε4+)应用statins治疗后血浆LDL水平显著降低(2.36±0.70比3.00±0.75,P相似文献   

19.
Cholinesterase inhibitors (ChEIs) have shown positive symptomatic effects on cognition, activities of daily living, and behavior in patients with Alzheimer's disease (AD). Rivastigmine is a slowly reversible ChEI that inhibits acetylcholinesterase and butyrylcholinesterase. We evaluated the effects of long-term rivastigmine treatment on cognitive function and plasma levels of ChE activity, and the relationship between ChE activity and cognition. Patients with mild AD (n = 11) treated with rivastigmine for 12 months were compared with matched groups of untreated patients with AD (n = 21) or mild cognitive impairment (MCI; n = 22) representing the natural course of the pre-clinical and very early stage of disease. For untreated AD patients, neuropsychological assessment was made at baseline and 12 months. Determination of ChE activity in plasma and assessment of global cognition, episodic memory, visuospatial ability, and attention were performed at 0 (baseline), 3, 6, and 12 months for treated AD patients and untreated MCI patients. At 12 months, cognitive function was slightly improved or maintained in mild AD patients treated with rivastigmine. In contrast, cognition was markedly worsened in untreated AD patients and unchanged or slightly worsened in untreated MCI patients. In the group of treated AD patients, there was a significant correlation between plasma ChE inhibition and cognition, particularly in relation to attention. This effect was most apparent at 3 months of treatment. In conclusion, a clear beneficial effect of rivastigmine was shown on cognitive function for patients with mild AD and plasma values of ChE inhibition were associated with attention.  相似文献   

20.
标准大骨瓣减压并颞肌贴敷术治疗大面积脑梗塞   总被引:6,自引:0,他引:6  
目的探讨外伤标准大骨瓣减压并脑组织表面颞肌贴敷术治疗大面积脑梗塞患者的效果。方法25例大面积脑梗塞患者采用大骨瓣减压及脑组织表面颞肌贴敷术进行治疗,同期22例患者行内科治疗,并比较其效果。结果在中线回复、患者死亡率、痊愈率三方面,手术治疗组优于常规内科治疗组,但病残率无明显差异。结论标准大骨瓣减压并颞肌贴敷术可降低大面积脑梗塞患者的死亡率,改善预后。  相似文献   

设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号